ECA Marcellus Trust I (ECTM)
OTCMKTS
· Delayed Price · Currency is USD
0.4600
-0.0300 (-6.12%)
Apr 24, 2025, 2:52 PM EDT
ECA Marcellus Trust I Revenue
In the year 2024, ECA Marcellus Trust I had annual revenue of $2.18M, down -24.60%. ECA Marcellus Trust I had revenue of $743.88K in the quarter ending December 31, 2024, with 8.36% growth.
Revenue
2.18M
Revenue Growth
-24.60%
P/S Ratio
4.02
Revenue / Employee
1.09M
Employees
2
Market Cap
8.75M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.18M | -709.58K | -24.60% |
Dec 31, 2023 | 2.88M | -8.74M | -75.18% |
Dec 31, 2022 | 11.62M | 5.33M | 84.63% |
Dec 31, 2021 | 6.30M | 4.59M | 269.63% |
Dec 31, 2020 | 1.70M | -2.44M | -58.92% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cyber App Solutions | 586.70K |
EXCO Resources | 394.03M |
Unit Corporation | 237.61M |
Pardee Resources Company | 50.63M |
Vantage Drilling International | 204.51M |
Granite Falls Energy, LLC | 409.95M |
Ferrellgas Partners | 1.89B |
ECA Marcellus Trust I News
- 2 months ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 5 months ago - ECA Marcellus Trust I declares $0.005 dividend - Seeking Alpha
- 5 months ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 5 months ago - Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 9 months ago - ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution - Business Wire
- 11 months ago - Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 11 months ago - Kontron introduces the XMC-ETH6 - Business Wire
- 1 year ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire